Skip to main
PSNL
PSNL logo

Personalis Inc (PSNL) Stock Forecast & Price Target

Personalis Inc (PSNL) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 70%
Buy 10%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

Personalis Inc demonstrated robust financial performance in its recent quarter, with a gross margin of 27.1% for 4Q24, marking a year-over-year increase of 50 basis points and exceeding expectations. The company's revenue from biopharma testing and services surged by 59%, reaching $51 million in 2024 compared to $32 million in 2023, driven by an improved customer mix and increased clinical test volumes. Furthermore, substantial growth in MRD testing revenue and successful collaborations with partners like Tempus indicate strong market demand and a favorable outlook for future operations.

Bears say

Personalis Inc experienced a significant decline in quarterly revenues, with 4Q24 revenue reported at $16.8 million, representing a 15% year-over-year decrease, which is well below earlier estimates. The company's operating expenses also fell but reflect ongoing financial challenges, highlighting slower than expected growth in both its biopharma and clinical diagnostics segments. Additionally, the steep drop in VA MVP revenue from $4.4 million in 3Q24 to $0.2 million in 4Q24 points to serious risks, including lower customer adoption rates and increasing competition, potentially undermining future revenue projections.

Personalis Inc (PSNL) has been analyzed by 10 analysts, with a consensus rating of Buy. 70% of analysts recommend a Strong Buy, 10% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Personalis Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Personalis Inc (PSNL) Forecast

Analysts have given Personalis Inc (PSNL) a Buy based on their latest research and market trends.

According to 10 analysts, Personalis Inc (PSNL) has a Buy consensus rating as of Jul 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Personalis Inc (PSNL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.